亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Tumor-homing CXCR4-expressing CTLs, Th1 and NK Cells, and Methods of Their Production and Use in Therapy of Cancer and Chronic Infections

詳細技術說明
None
*Abstract
The Innovators discovered that hypoxia and small-molecule activators of hypoxia-inducible HIF-1-alpha (hypoxia mimetics) induce double-positive (CXCR4 /GZMB) CD 8 effector T cells. They in turn can migrate to tumor-produced CXCL12 and effectively kill cancer cells.BackgroundEffectiveness of immunity depends on proper homing of functionally-distinct subsets of T cells to different tissues. The ability of cytotoxic CD8 effector T cells (CTL/Teff), Th1- and NK cells to migrate to tumor- and chronically-inflamed tissues is critical for their ability eliminate cancer cells and intracellular infections. The induction of CXCR4 on killer cells could allow them to acquire a Trojan Horse status and exploit the pathway used by the tumors to attract suppressive cells, to enter tumors and kill cancer cells.Benefits1. The cells described by the innovators are simple to generate and require only low-cost procedures or reagents2. In case of hypoxia, no chemicals are used at all, facilitating incorporation of the innovators method into existing protocols 3. The possibility of generating ing cells with mixed phenotype for additional forms of treatment of cancer, infections, allergy, autoimmunity, and transplant rejectionApplicationUS Provisional Application FiledStage of DevelopmentIn Vitro Data
*Principal Investigation

Name: Pawel Kalinski, Assistant Professor of Surgery

Department: Med-Surgery


Name: Ravikumar Muthuswamy

Department: Med-Surgery

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備